Evidence map›Paper›PMID 25065017›Full record

Trial reportSchizophrenia bulletin2015

Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial.

William R McFarlane, Bruce Levin, Lori Travis, F Lee Lucas, Sarah Lynch, Mary Verdi, Deanna Williams, Steven Adelsheim, Roderick Calkins, Cameron S Carter and 11 more

Erratum issued Registry-linked trialAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Schizophrenia bulletin, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00531518 (Early Detection and Intervention for the Prevention of Psychosis Project), which is not on this map. Cited by 57 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00531518 nacompletednot on this map

Early Detection and Intervention for the Prevention of Psychosis Project

TypeinterventionalSponsorMaineHealthRan2007 to 2013Enrolled292ConditionsSchizophrenia, Bipolar Disorder, Depression, Psychotic DisordersArmsaripiprazole, fluoxetine, bupropion, sertraline, lamotrigine
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Quality of life in individuals at clinical high risk for psychosis: A systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Psychological interventions for psychosis in adolescents.The Cochrane database of systematic reviews · 2020
    Pooled it
  5. Interventions for prodromal stage of psychosis.The Cochrane database of systematic reviews · 2019
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. A Multicentre, Randomised, Controlled Trial of a Combined Clinical Treatment for First-Episode Psychosis.International journal of environmental research and public health · 2021
    Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

William R McFarlaneTufts University School of Medicine, Boston, MA; Maine Medical Center Research Institute, Portland, ME; mcfarw@mmc.org.
Bruce LevinMailman School of Public Health, Columbia University, New York, NY;
Lori TravisMaine Medical Center Research Institute, Portland, ME;
F Lee LucasMaine Medical Center Research Institute, Portland, ME;
Sarah LynchMaine Medical Center Research Institute, Portland, ME;
Mary VerdiMaine Medical Center Research Institute, Portland, ME;
Deanna WilliamsMaine Medical Center Research Institute, Portland, ME;
Steven AdelsheimDepartment of Psychiatry, Stanford University School Of Medicine, Palo, Alto, CA;
Roderick CalkinsMarion County Health Department, Salem, OR;
Cameron S CarterDepartment of Psychiatry, University of California at Davis, Sacramento, CA;
Barbara CornblattZucker Hillside Hospital, Glen Oaks, NY;
Stephan F TaylorDepartment of Psychiatry, University of Michigan, Ann Arbor, MI; Washtenaw Community Health Organization, Ypsilanti, MI;
Andrea M AutherZucker Hillside Hospital, Glen Oaks, NY;
Bentson McFarlandDepartment of Psychiatry, Oregon Health Sciences University, Portland, OR;
Ryan MeltonPortland State University, Portland, OR;
Margaret MiglioratiUniversity of New Mexico, Albuquerque, NM;
Tara NiendamDepartment of Psychiatry, University of California at Davis, Sacramento, CA;
J Daniel RaglandDepartment of Psychiatry, University of California at Davis, Sacramento, CA;
Tamara SalePortland State University, Portland, OR; Mid-Valley Behavioral Care Network, Salem, OR.
Melina SalvadorDepartment of Psychiatry, Stanford University School Of Medicine, Palo, Alto, CA;
Elizabeth SpringWashtenaw Community Health Organization, Ypsilanti, MI;

Funding

4/9-Predictors and Mechanisms of Conversion to PsychosisU01MH081857 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI CORNBLATT, BARBARA A. · 2008 to 2018
$6.2M
CHARACTERIZATION OF PRODROMAL SCHIZOPHRENIAR01MH061523 · NIMH · LONG ISLAND JEWISH MEDICAL CENTER · PI CORNBLATT, BARBARA A. · 2000 to 2009
$3.6M
Brain mechanisms of impaired episodic memory in schizophreniaR01MH084895 · NIMH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI RAGLAND, JOHN D · 2010 to 2013
$1.4M
NIMH NIH HHS R01 MH061523NIMH NIH HHS R01 MH084895NIMH NIH HHS U01 MH081857
6 · The paper itself

Abstract

objectiveTo test effectiveness of the Early Detection, Intervention, and Prevention of Psychosis Program in preventing the onset of severe psychosis and improving functioning in a national sample of at-risk youth.

methodsIn a risk-based allocation study design, 337 youth (age 12-25) at risk of psychosis were assigned to treatment groups based on severity of positive symptoms. Those at clinically higher risk (CHR) or having an early first episode of psychosis (EFEP) were assigned to receive Family-aided Assertive Community Treatment (FACT); those at clinically lower risk (CLR) were assigned to receive community care. Between-groups differences on outcome variables were adjusted statistically according to regression-discontinuity procedures and evaluated using the Global Test Procedure that combined all symptom and functional measures.

resultsA total of 337 young people (mean age: 16.6) were assigned to the treatment group (CHR + EFEP, n = 250) or comparison group (CLR, n = 87). On the primary variable, positive symptoms, after 2 years FACT, were superior to community care (2 df, p < .0001) for both CHR (p = .0034) and EFEP (p < .0001) subgroups. Rates of conversion (6.3% CHR vs 2.3% CLR) and first negative event (25% CHR vs 22% CLR) were low but did not differ. FACT was superior in the Global Test (p = .0007; p = .024 for CHR and p = .0002 for EFEP, vs CLR) and in improvement in participation in work and school (p = .025).

conclusionFACT is effective in improving positive, negative, disorganized and general symptoms, Global Assessment of Functioning, work and school participation and global outcome in youth at risk for, or experiencing very early, psychosis.

Indexed as

AdolescentAdultAnti-Anxiety AgentsAntidepressive AgentsAntimanic AgentsAntipsychotic AgentsAnxiety DisordersChildCommunity Mental Health ServicesEarly DiagnosisEarly Medical InterventionEmployment, SupportedFamily TherapyFemaleHumansLongitudinal StudiesAnti-Anxiety AgentsAntidepressive AgentsAntimanic AgentsAntipsychotic Agentsassertive community treatmentfamily psychoeducationmultifamily groupschizophreniasupported educationsupported employment

Identifiers

PMID25065017
PMCPMC4266296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.